Stryker Co. (NYSE:SYK) Receives $331.52 Average Target Price from Analysts

Stryker Co. (NYSE:SYKGet Free Report) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $331.52.

Several brokerages recently commented on SYK. Roth Mkm increased their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Truist Financial raised their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a report on Wednesday, January 31st. UBS Group raised their target price on Stryker from $289.00 to $297.00 and gave the stock a “neutral” rating in a research report on Thursday, November 9th. Citigroup upped their target price on shares of Stryker from $340.00 to $362.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st.

Get Our Latest Research Report on SYK

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 262,725 shares of company stock worth $86,880,191. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Stryker by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after purchasing an additional 143,631 shares in the last quarter. BlackRock Inc. increased its position in shares of Stryker by 4.8% during the second quarter. BlackRock Inc. now owns 25,862,485 shares of the medical technology company’s stock worth $7,890,386,000 after purchasing an additional 1,188,957 shares in the last quarter. State Street Corp increased its position in Stryker by 2.4% during the 2nd quarter. State Street Corp now owns 14,393,817 shares of the medical technology company’s stock valued at $4,402,083,000 after buying an additional 340,114 shares in the last quarter. Geode Capital Management LLC raised its stake in Stryker by 3.0% in the second quarter. Geode Capital Management LLC now owns 6,135,106 shares of the medical technology company’s stock valued at $1,865,989,000 after buying an additional 181,068 shares during the last quarter. Finally, Morgan Stanley raised its position in shares of Stryker by 21.7% in the 4th quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock valued at $1,461,753,000 after purchasing an additional 1,066,751 shares during the last quarter. Institutional investors own 76.24% of the company’s stock.

Stryker Stock Up 0.9 %

SYK stock opened at $341.96 on Thursday. The company has a market capitalization of $129.92 billion, a price-to-earnings ratio of 41.45, a price-to-earnings-growth ratio of 2.76 and a beta of 0.90. The business’s 50 day moving average price is $307.59 and its two-hundred day moving average price is $289.39. Stryker has a fifty-two week low of $249.98 and a fifty-two week high of $346.59. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58.

Stryker (NYSE:SYKGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the business earned $3.00 EPS. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, analysts forecast that Stryker will post 11.87 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.94%. Stryker’s dividend payout ratio is currently 38.79%.

About Stryker

(Get Free Report

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Recommended Stories

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.